DDInter1236 DDInter1676
Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactivation and euphoria. The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Modafinil activates glutamatergic circuits while inhibiting GABA.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Modafinil {u} (Compound) resembles {v} (Compound) Fentanyl
Modafinil {u} (Compound) resembles {v} (Compound) Fenoprofen
Modafinil {u} (Compound) binds {v} (Gene) CYP1A2
Modafinil {u} (Compound) upregulates {v} (Gene) HP
Modafinil {u} (Compound) palliates {v} (Disease) multiple sclerosis
Modafinil {u} (Compound) is included by {v} (Pharmacologic Class) Central Nervous System Stimulation
Modafinil {u} (Compound) downregulates {v} (Gene) UBQLN2
Modafinil {u} (Compound) causes {v} (Side Effect) Hepatic enzyme increased
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cyclophosphamide
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pazopanib
Modafinil (Compound) resembles Fentanyl (Compound)
Modafinil (Compound) resembles Fenoprofen (Compound)
Modafinil (Compound) binds CYP1A2 (Gene)
Modafinil (Compound) upregulates HP (Gene)
Modafinil (Compound) palliates multiple sclerosis (Disease)
Modafinil (Compound) is included by Central Nervous System Stimulation (Pharmacologic Class)
Modafinil (Compound) downregulates UBQLN2 (Gene)
Modafinil (Compound) causes Hepatic enzyme increased (Side Effect)
Modafinil may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide
Modafinil may cause a minor interaction that can limit clinical effects when taken with Pazopanib